Nephrotoxicity of recent anti-cancer agents

被引：75
作者：
Lameire, Norbert [1 ]
机构：
[1] Univ Hosp, 185 Pintelaan, B-9000 Ghent, Belgium
来源：
CLINICAL KIDNEY JOURNAL | 2014年 / 7卷 / 01期
关键词：
anti-angiogenesis drugs and cancer; anti-cancer drugs and nephrotoxicity; androgen deprivation therapy and AKI;
D O I：
10.1093/ckj/sft135
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Cancer patients may develop a variety of kidney lesions that impair not only their immediate survival but also limit the adequate treatment of the underlying malignant process. This review summarizes the nephrotoxic potential of some of the most recently developed anti-cancer drugs, focusing on those interfering with the vascular endothelial growth factor and epidermal growth factor receptor pathways and mammalian target of rapamycin inhibitors. Thrombotic microangiopathy (haemolytic-uraemic syndrome), proteinuria, hypertension and magnesium depletion are the most common side effects. Also the risk for developing acute kidney injury in patients with advanced prostate cancer undergoing androgen deprivation therapy is discussed.
引用
收藏
页码：11 / 22
页数：12
相关论文
共 112 条
[91]   Onconephrology: The Latest Frontier in the War against Kidney Disease [J].
Salahudeen, Abdulla K. ;
Bonventre, Joseph V. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (01) :26-30
[92]   Small increases in serum creatinine are associated with prolonged ICU stay and increased hospital mortality in critically ill patients with cancer [J].
Samuels, Joshua ;
Ng, Chaan S. ;
Nates, Joseph ;
Price, Kristen ;
Finkel, Kevin ;
Salahudeen, Abdulla ;
Shaw, Andrew .
SUPPORTIVE CARE IN CANCER, 2011, 19 (10) :1527-1532
[93]  
Satariano WA, 2000, BAS CLIN ON, P477
[94]   Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma [J].
Shahinian, VB ;
Kuo, YF ;
Freeman, JL ;
Orihuela, E ;
Goodwin, JS .
CANCER, 2005, 103 (08) :1615-1624
[95]   Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors [J].
Snider, Kelly L. ;
Maitland, Michael L. .
TARGETED ONCOLOGY, 2009, 4 (02) :67-76
[96]   Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer [J].
Thomas, GV ;
Tran, C ;
Mellinghoff, IK ;
Welsbie, DS ;
Chan, E ;
Fueger, B ;
Czernin, J ;
Sawyers, CL .
NATURE MEDICINE, 2006, 12 (01) :122-127
[97]   Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients [J].
Vincenzi, B. ;
Galluzzo, S. ;
Santini, D. ;
Rocci, L. ;
Loupakis, F. ;
Correale, P. ;
Addeo, R. ;
Zoccoli, A. ;
Napolitano, A. ;
Graziano, F. ;
Ruzzo, A. ;
Falcone, A. ;
Francini, G. ;
Dicuonzo, G. ;
Tonini, G. .
ANNALS OF ONCOLOGY, 2011, 22 (05) :1141-1146
[98]   Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome [J].
Vincenzi, Bruno ;
Santini, Daniele ;
Galluzzo, Sara ;
Russo, Antonio ;
Fulfaro, Fabio ;
Silletta, Marianna ;
Battistoni, Fabrizio ;
Rocci, Laura ;
Zobel, Bruno Beomonte ;
Adamo, Vincenzo ;
Dicuonzo, Giordano ;
Tonini, Giuseppe .
CLINICAL CANCER RESEARCH, 2008, 14 (13) :4219-4224
[99]  
WALKER RW, 1989, CANCER, V64, P1017, DOI 10.1002/1097-0142(19890901)64:5<1017::AID-CNCR2820640508>3.0.CO
[100]  
2-N
3456789101112